Cancer drug developer Endocyte files for IPO
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
Health Care Businesses
Articles
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Medco to acquire United BioSource for $710M
Medco operates an automated pharmacy and distribution center in Whitestown in Boone County, and it plans to employ more than
1,400 people there by 2012.
Bedsore preventer turns to detection
Changes in reimbursement could fuel market for WoundVision’s product.
Arcadia sees smaller loss, extends WellPoint pact
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.
Lilly among bidders for Denmark company, source says
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
Hill-Rom raises profit forecast after quarterly earnings jump
The Batesville-based maker of hospital beds and furniture announced Wednesday night that it earned $30.6 million in its third quarter, up from $20.2 million in the same quarter of 2009.
Lilly loses appeal over patent for cancer drug Gemzar
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
Lilly completes $180 million acquisition of Alnara
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
Lilly to cut 170 manufacturing jobs by year’s end
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
Medical device maker plans Warsaw expansion
Biomet could add about 280 jobs with the $26 million project, which would lead to some manufacturing being transferred from
New Jersey.
Home medical supply firm grows as industry boom approaches
David Hartley pulled $85,000 from his savings six years ago to buy Home Health Depot Inc. Nearly six years later, Hartley
has reinvented the Indianapolis-based home medical equipment supplier, growing from a single office in Greenwood to 12 locations
in Indiana and Illinois—and increasing annual revenue from $300,000 to more than $6.7 million.
Men on Viagra, Cialis show triple rate of sex diseases in study
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly’s Cialis, may be more likely to
engage in unsafe sex than nonusers.
Lilly acquires biotech company with pancreatic drug
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
Lilly’s Effient steps forward, then back
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
Lilly, Amylin stock rises on drug postponement
Roche Holding AG’s decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
Lilly layoffs pare communications department
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications
staff. Most of that staff is based in Indianapolis.